J&J CEO says people may need annual Covid vaccine shots for the next several years

Business News

Alex Gorsky, Chairman and CEO of Johnson & Johnson, celebrates the 75th anniversary of his company’s listing on the floor at the New York Stock Exchange, September 17, 2019.

Brendan McDermid | Reuters

People may need to get vaccinated against Covid-19 annually, just like seasonal flu shots, over the next several years, Johnson & Johnson CEO Alex Gorsky told CNBC on Tuesday.

You Might Like

“Unfortunately, as [the virus] spreads it can also mutate,” he told CNBC’s Meg Tirrell during a Healthy Returns Spotlight event. “Every time it mutates, it’s almost like another click of the dial so to speak where we can see another variant, another mutation that can have an impact on its ability to fend of antibodies or to have a different kind of response not only to a therapeutic but also to a vaccine.”

Public health officials and infectious disease experts have said there is a high likelihood that Covid-19 will become an endemic disease, meaning it will become present in communities at all times, though likely at lower levels than it is now. Health officials will have to continuously watch for new variants of the virus, so scientists can produce vaccines to fight them, medical experts say.

Gorsky’s comment came after J&J said Friday it applied for an emergency use authorization from the Food and Drug Administration for its coronavirus vaccine. Unlike Pfizer’s and Moderna’s vaccines, which require two doses given about three to four weeks apart, J&J’s only requires one dose, easing logistics for health-care providers.

U.S. officials and Wall Street analysts are eagerly anticipating the authorization of J&J’s vaccine, which could happen as early as this month. President Joe Biden is trying to pick up the pace of vaccinations in the U.S. and experts say his administration will need an array of drugs and vaccines to defeat the virus, which has killed more than 450,000 Americans over the last year, according to data compiled by Johns Hopkins University.

The Department of Health and Human Services announced in August that it reached a deal with Janssen, J&J’s pharmaceutical subsidiary, worth approximately $1 billion for 100 million doses of its vaccine. The deal gives the federal government the option to order an additional 200 million doses, according to the announcement.

This is a developing story. Please check back for updates.

Articles You May Like

American woman reportedly brutally beaten by growling, ‘pure evil,’ fake taxi driver on Caribbean island: ‘I fought for my life’
ABC’s Jon Karl Tries To Veep-Shame Marco Rubio, Gets SCHOOLED
Morning Joe To NBC: Fire Ronna McDaniel! We’ll Never Have Her On The Show!
CRIME PAYS: New York City Begins Distributing Pre-Paid Debit Cards to Illegal Immigrants
Russia will not stop with Ukraine, US ambassador warns

Leave a Reply

Your email address will not be published. Required fields are marked *